Avalo Therapeutics Sees Unusually High Options Volume (NASDAQ:AVTX)

Avalo Therapeutics, Inc. (NASDAQ:AVTX) was the recipient of some unusual options trading activity on Monday. Traders purchased 6,807 put options on the stock. This is an increase of 228% compared to the typical daily volume of 2,076 put options.

Insider Buying and Selling at Avalo Therapeutics

In other news, insider Mittie Doyle sold 25,492 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $16.15, for a total value of $411,695.80. Following the sale, the insider owned 3,622 shares in the company, valued at approximately $58,495.30. This represents a 87.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Paul Varki sold 75,063 shares of the stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $20.17, for a total transaction of $1,514,020.71. Following the transaction, the insider directly owned 3,634 shares in the company, valued at $73,297.78. The trade was a 95.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 138,078 shares of company stock worth $2,501,346 in the last ninety days. 4.46% of the stock is owned by insiders.

Institutional Trading of Avalo Therapeutics

A number of large investors have recently modified their holdings of AVTX. Patient Square Capital LP bought a new position in Avalo Therapeutics in the 3rd quarter worth approximately $1,271,000. UBS Group AG raised its stake in Avalo Therapeutics by 956.9% during the 4th quarter. UBS Group AG now owns 477,816 shares of the company’s stock valued at $8,677,000 after acquiring an additional 432,608 shares in the last quarter. Cantor Fitzgerald L. P. acquired a new position in Avalo Therapeutics during the 3rd quarter worth $1,083,000. Moody Aldrich Partners LLC bought a new position in shares of Avalo Therapeutics in the fourth quarter worth $2,419,000. Finally, Boothbay Fund Management LLC increased its holdings in shares of Avalo Therapeutics by 1,916.6% during the third quarter. Boothbay Fund Management LLC now owns 228,297 shares of the company’s stock valued at $2,902,000 after purchasing an additional 216,976 shares during the period. Institutional investors and hedge funds own 87.06% of the company’s stock.

Avalo Therapeutics Stock Performance

Shares of Avalo Therapeutics stock traded up $0.10 on Monday, reaching $13.20. 411,877 shares of the company were exchanged, compared to its average volume of 1,084,684. The firm has a market cap of $693.92 million, a price-to-earnings ratio of -2.41 and a beta of 0.83. Avalo Therapeutics has a 1-year low of $4.20 and a 1-year high of $24.27. The company’s 50-day moving average is $15.80 and its two-hundred day moving average is $16.36.

Avalo Therapeutics (NASDAQ:AVTX) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.02. As a group, sell-side analysts forecast that Avalo Therapeutics will post -2.72 earnings per share for the current year.

Analyst Ratings Changes

AVTX has been the topic of several research reports. Weiss Ratings cut Avalo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, May 26th. Piper Sandler reiterated an “overweight” rating and issued a $60.00 target price (up from $48.00) on shares of Avalo Therapeutics in a research report on Monday, May 11th. Wolfe Research assumed coverage on Avalo Therapeutics in a research report on Thursday, April 9th. They set an “outperform” rating and a $48.00 price target on the stock. BTIG Research raised their price objective on Avalo Therapeutics from $40.00 to $58.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Finally, Mizuho lifted their price objective on shares of Avalo Therapeutics from $39.00 to $45.00 and gave the stock an “outperform” rating in a report on Thursday, May 14th. Eleven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Avalo Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $48.13.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.